SCG Cell Therapy, a clinical-stage biotech firm based in Singapore, saw its net loss widen in 2022 as it continues to develop novel immunotherapies for infections and their associated cancers.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
